Drug developers rethink submission strategies amidst FDA’s new AI tool As the FDA begins AI-assisted regulatory review, the industry ponders how to best tailor their submissions.

https://www.drugdiscoverynews.com/drug-developers-rethink-submission-strategies-amidst-fda-s-new-ai-tool-16561?utm_campaign=DDN_Newsletter_Science%20Spotlight&utm_medium=email&_hsenc=p2ANqtz-9YMbHji526ttjf5ilvNSv8wHzs_j9NWgF0AZWOzYXTkoKQyBMQd6Qcbk004OZsILddqy8wb4leOsZXPP32oD7LnMmemw&_hsmi=376093394&utm_content=376093394&utm_source=hs_email